AJCC/UICC第八版分期系统可预测甲状腺乳头状癌复发
该研究基于法国单中心4124例甲状腺乳头状癌手术患者,评估AJCC/UICC第七版与第八版分期系统对复发的预测能力。第八版对复发的预测优于第七版,可作为风险分层工具。
要点
- 第八版AJCC/UICC分期可预测甲状腺乳头状癌复发,优于第七版。
核心结论
- AJCC/UICC第八版分期系统可作为预测甲状腺乳头状癌复发的新工具,有助于风险分层。
研究设计与样本
- 回顾性队列研究,纳入1985至2015年间在法国高容量内分泌外科中心接受手术的4124例甲状腺乳头状癌患者。
主要发现
- 第八版对复发的预测优于第七版。
临床怎么用
- 临床可采用第八版AJCC/UICC分期对PTC患者进行复发风险分层。
- 评估复发风险时需结合其他分子和病理预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The AJCC/UICC classification is widely used for predicting survival in papillary thyroid cancer (PTC), but has not been evaluated as a predictor of recurrence. The hypothesis of this study was that the eighth edition of the AJCC system can be used in this novel way. METHODS: All patients in the study underwent surgery for PTC at a high-volume endocrine surgery centre in France between 1985 and 2015. The seventh and eighth editions of the AJCC/UICC staging system for PTC were employed to predict recurrence and disease-specific survival using the Kaplan-Meier and log rank tests. RESULTS: Among 4124 patients (79·7 per cent female), median age was 50 (i.q.r. 38-60) years; 3906 patients (94·7 per cent) underwent total thyroidectomy, with lymph node dissection in 2495 (60·5 per cent). The eighth edition of the AJCC/UICC staging system placed 91·8, 7·1, 0·4 and 0·7 per cent of patients in stages I-IV respectively. After reclassifying patients from the seventh to the eighth AJCC/UICC edition, the disease was downstaged in 23·8 per cent. Over a median follow-up of 7 years, 260 patients (6·4 per cent) developed recurrent disease, including 5·2 per cent of patients with stage I, 19·6 per cent with stage II, 59 per cent with stage III and 50 per cent with stage IV disease, according to the eighth edition. The eighth edition was a better predictor of recurrence than the seventh edition. CONCLUSION: The eighth edition of the AJCC/UICC staging system appears to be a novel tool for predicting PTC recurrence, which is a meaningful outcome for this indolent disease. The eighth edition can be used to risk-stratify patients, keeping in mind that other molecular and pathological predictive factors must be integrated into the assessment of recurrence risk.
引用
- Chereau N, Oyekunle TO, Zambeli-Ljepović A, et al. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system. Br J Surg. 2019. PMID: 31012500. doi:10.1002/bjs.11145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。